Institute of Biomedicine & Department of Cell Biology, Jinan University, Guangzhou, China.
Department of Pharmacology, Jinan University, Guangzhou, China.
J Alzheimers Dis. 2016;51(4):985-90. doi: 10.3233/JAD-151121.
Neurotoxic amyloid-β (Aβ) peptide causing cognitive function disabilities is one of the most characteristic pathological features in Alzheimer's disease (AD). A novel fusion protein, TAT-haFGF, was administrated to AβPP/PS1 transgenic mice by intravenous (IV) injection and intranasal (IN) delivery, respectively, for 5 weeks to compare the pharmacodynamics between the two routes of administration. Our results showed that IN administration of TAT-haFGF improved cognition and reduced Aβ plaques more significantly in AβPP/PS1 mice, when compared with IV injection. Our new findings suggest that TAT-haFGF might be a promising new therapy to attenuate AD pathological process.
神经毒性淀粉样β（Aβ）肽导致认知功能障碍是阿尔茨海默病（AD）最具特征性的病理特征之一。新型融合蛋白 TAT-haFGF 通过静脉（IV）注射和鼻内（IN）给药分别给予 AβPP/PS1 转基因小鼠，进行 5 周治疗，以比较两种给药途径的药效学。我们的结果表明，与 IV 注射相比，TAT-haFGF 的 IN 给药在 AβPP/PS1 小鼠中更显著地改善了认知功能并减少了 Aβ斑块。我们的新发现表明，TAT-haFGF 可能是一种有前途的新疗法，可以减轻 AD 的病理过程。
